Roser Sala-Llonch1,2, Albert Lladó3,4, José Contador5, Agnès Pérez-Millan5,1, Nuria Guillen5, Adrià Tort-Merino5, Mircea Balasa5,6, Neus Falgàs5,7,8, Jaume Olives5, Magdalena Castellví5, Sergi Borrego-Écija9, Beatriz Bosch5, Guadalupe Fernández-Villullas5, Oscar Ramos-Campoy5, Anna Antonell5, Nuria Bargalló10, Raquel Sanchez-Valle5,11. 1. Institute of Neurosciences. Department of Biomedicine, Faculty of Medicine, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. 2. Biomedical Imaging Group, Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain. 3. Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain. allado@clinic.cat. 4. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain. allado@clinic.cat. 5. Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain. 6. Atlantic Fellow for Equity in Brain Health, Global Brain Heath Institute, Trinity College Institute of Neuroscience, Dublin, Ireland. 7. Atlantic Fellow for Equity in Brain Health, Global Brain Heath Institute, Department of Neurology, University of California, San Francisco, CA, USA. 8. Department of Neurology, Memory & Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. 9. Department of Neurology, Fundació Sanitària Mollet, Mollet del Vallés, Barcelona, Spain. 10. Image Diagnostic Centre Radiology Department, Hospital Clínic de Barcelona, Magnetic Resonance Image Core facility Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 11. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.
Abstract
BACKGROUND: MRI atrophy predicts cognitive status in AD. However, this relationship has not been investigated in early-onset AD (EOAD, < 65 years) patients with a biomarker-based diagnosis. METHODS: Forty eight EOAD (MMSE ≥ 15; A + T + N +) and forty two age-matched healthy controls (HC; A - T - N -) from a prospective cohort underwent full neuropsychological assessment, 3T-MRI scan and lumbar puncture at baseline. Participants repeated the cognitive assessment annually. We used linear mixed models to investigate whether baseline cortical thickness (CTh) or subcortical volume predicts two-year cognitive outcomes in the EOAD group. RESULTS: In EOAD, hemispheric CTh and ventricular volume at baseline were associated with global cognition, language and attentional/executive functioning 2 years later (p < 0.0028). Regional CTh was related to most cognitive outcomes (p < 0.0028), except verbal/visual memory subtests. Amygdalar volume was associated with letter fluency test (p < 0.0028). Hippocampal volume did not show significant associations. CONCLUSION: Baseline hemispheric/regional CTh, ventricular and amygdalar volume, but not the hippocampus, predict two-year cognitive outcomes in EOAD.
BACKGROUND: MRI atrophy predicts cognitive status in AD. However, this relationship has not been investigated in early-onset AD (EOAD, < 65 years) patients with a biomarker-based diagnosis. METHODS: Forty eight EOAD (MMSE ≥ 15; A + T + N +) and forty two age-matched healthy controls (HC; A - T - N -) from a prospective cohort underwent full neuropsychological assessment, 3T-MRI scan and lumbar puncture at baseline. Participants repeated the cognitive assessment annually. We used linear mixed models to investigate whether baseline cortical thickness (CTh) or subcortical volume predicts two-year cognitive outcomes in the EOAD group. RESULTS: In EOAD, hemispheric CTh and ventricular volume at baseline were associated with global cognition, language and attentional/executive functioning 2 years later (p < 0.0028). Regional CTh was related to most cognitive outcomes (p < 0.0028), except verbal/visual memory subtests. Amygdalar volume was associated with letter fluency test (p < 0.0028). Hippocampal volume did not show significant associations. CONCLUSION: Baseline hemispheric/regional CTh, ventricular and amygdalar volume, but not the hippocampus, predict two-year cognitive outcomes in EOAD.
Authors: Lilian Calderón-Garcidueñas; Jacqueline Hernández-Luna; Partha S Mukherjee; Martin Styner; Diana A Chávez-Franco; Samuel C Luévano-Castro; Celia Nohemí Crespo-Cortés; Elijah W Stommel; Ricardo Torres-Jardón Journal: Toxics Date: 2022-03-25